Hepatitis C (cont.)
Mary D. Nettleman, MD, MS, MACP
Mary D. Nettleman, MD, MS, MACP is the Chair of the Department of Medicine at Michigan State University. She is a graduate of Vanderbilt Medical School, and completed her residency in Internal Medicine and a fellowship in Infectious Diseases at Indiana University.
Jay W. Marks, MD
Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.
In this Article
- Hepatitis C infection (HCV, hep C) facts
- What is hepatitis C infection?
- What is the nature (biology) of the hepatitis C virus?
- How does liver damage occur in hepatitis C infection?
- How is hepatitis C virus spread, is it contagious, and how can transmission be prevented?
- What are the symptoms of hepatitis C infection?
- What conditions outside the liver are associated with hepatitis C infection?
- What is the usual progression of chronic hepatitis C infection?
- Who is at high risk and should be tested for hepatitis C infection?
- What are the diagnostic tests for hepatitis C virus and how are they used to diagnose hepatitis C infection?
- What is the role of a liver biopsy in the management of chronic hepatitis C infection?
- What is the treatment for hepatitis C infection?
- Who should receive antiviral therapy for hepatitis C infection?
- What are the different patterns of response to antiviral treatment?
- What are the goals of therapy for hepatitis C infection?
- What are the therapy options for previously untreated patients with chronic hepatitis C infection?
- How are relapses and nonresponders treated?
- Should individuals with acute hepatitis C infection be treated?
- What are the side effects of treatment for hepatitis C infection?
- What about liver transplantation for hepatitis C infection?
- What is the current research and what is in the future for hepatitis C infection?
- Find a local Gastroenterologist in your town
Who should receive antiviral therapy for hepatitis C virus infection?
Current treatment options are imperfect (see below). Patients with HCV infection should discuss treatment options with a physician who is experienced in treating the disease. Treatment is recommended in patients at increased risk for cirrhosis unless there are reasons that would make treatment unsafe. According to the National Institutes of Health (NIH) persons at increased risk for cirrhosis would include those with HCV infection and:
- Persistent elevation of ALT (alanine aminotransferase, a liver enzyme in the blood)
- High levels of HCV RNA in the blood
- Evidence of early fibrosis (scarring) or moderate inflammation and injury of liver cells on liver biopsy
The NIH also recommends treatment for patients who are co-infected with HCV and HIV, because these patients have a more rapid course of liver injury.
These are general guidelines. Patients and providers may decide that treatment is needed for other reasons. For example, HCV infection may cause cryoglobulinemia. (See above.) Persistent cryoglobulinemia may be a reason for treating hepatitis C. Newer therapies may be offered to selected patients in research settings.
Individuals who should not be treated with antiviral therapy include those who are unable to comply with the treatment schedule, have reasons that may make treatment unsafe (for example, allergy to the medications), have received a solid organ transplant, are pregnant or unwilling to practice adequate contraception during treatment, or who have reversible serious untreated conditions such as unstable heart disease, uncontrolled high blood pressure, or untreated major depression.
Patients with unstable (decompensated) cirrhosis are at high risk for complications for treatment and usually do not receive medical treatment except in research settings. Fundamentally, the decision regarding antiviral therapy in chronic HCV infection should be tailored to the individual patient with careful consideration of the risks and benefits.
All patients with HCV should be vaccinated against hepatitis B and hepatitis A. They also should be counseled on measures to prevent the spread of HCV and eliminating alcohol use. Finally, risk behaviors for HCV overlap with those of HIV, and all patients with HCV should be tested for HIV.
Patient Comments
Viewers share their comments
http://www.medicinenet.com/hepatitis_c/article.htm
Women's Health
Find out what women really need.
Updated & New
